All News

The Food and Drug Administration granted a priority review to epcoritamab for certain patients with large B-cell lymphoma, an aggressive type of blood cancer.

A routine can feel so comfortable that change is hard. So, when my annual mammogram and cancer checkup was delayed, I tried hard not to sweat the small stuff.

A woman whose husband was diagnosed with ocular melanoma at 28 years old opens up about her experiences navigating the cancer world and her search for a supportive community.

Watch Dr. Aditya Bardia, Dr. Seth A. Wander and Dr. Laura M. Spring answer questions about HR-positive disease during the CURE Educated Patient Metastatic Breast Cancer Summit.

One expert said that the FDA approval of the antibody-drug conjugate Elahere represents a new treatment option for patients with folate receptor alpha-positive, platinum resistant ovarian cancer.

Childhood cancer survivors who had high daily sugar intake — especially when it came to sweetened beverages — had an increased risk of premature aging-related health complications, according to recent research.

Thanksgiving can be a stressful time for those with cancer, but it doesn’t have to be. I learned that it can also be a time filled with love and joy.

A nonprofit organization aims to connect patients, caregivers and loved ones affected by sarcoma while educating those about the rare cancer.

Watch Dr. Laura M. Spring, from Massachusetts General Hospital in Boston, discuss treatment in third line and beyond for hormone receptor-positive breast cancer, during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about clinical trials for patients with multiple myeloma.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about disparities in the multiple myeloma space.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the precursors to multiple myeloma, MGUS and smoldering myeloma.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the risk of infection for patients with multiple myeloma.

CURE® surveyed its audience to see if cancer and the COVID-19 virus are changing their Thanksgiving plans. Here’s what they had to say.

As a recovering addict, I was nervous about the painkillers that would come alongside my cancer treatment, but I soon learned that they would be needed.

Though remission rates for children who underwent CAR-T cell therapy did not differ based on socioeconomic status, accessibility gaps remain.

Watch Dr. Seth A. Wander, from Massachusetts General Hospital in Boston, discuss the first- and second-line treatment of hormone receptor-positive breast cancer, during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

Think twice before telling me that there is a "good" type of cancer or that I should "just be lucky my daughter is still alive."

The recent FDA approval of Libtayo for advanced non-small cell lung cancer added yet another option for the treatment of patients with the disease.

When my wife surprised me with a prostate cancer awareness T-shirt, I realized that those small gestures matter the most.

From “Star Trek” actors supporting the Pancreatic Cancer Action Network to Michelle Obama meeting with a sarcoma survivor and an update on Jane Fonda’s cancer, here’s what’s happening in the cancer space this week.

Zolbetuximab plus the chemotherapy regimen mFOLFOX6 improved progression-free survival and overall survival in certain patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

An expert writes about his experience as a sarcoma medical oncologist and how the field may progress with several therapies in the pipeline.

A 17-year survivor shares her experience of getting diagnosed with mesothelioma at 36, when people with this cancer are typically diagnosed at a much older age and given months to live.

As a cancer survivor, I can relate to the lyrics of the Beatles’ song, “Let it Be.”

Brandi Benson was thousands of miles away from home serving in the military when she received her cancer diagnosis. Today she advises others going through their own journey to not give up.

Tecvayli, which was recently approved for pretreated relapsed/refractory myeloma, is a “much more convenient” treatment option than CAR-T cell therapy, one expert said.

The first patient was enrolled in a phase 1 trial analyzing MTX110 in patients with recurrent glioblastoma, an aggressive type of brain cancer.